US Tariffs on Japan: Status as of October 2026

Key takeaways
As of October 2026, most goods from Japan face a Section 301 duty that tops the normal US rate up to a combined 12.5%, replacing the 15% IEEPA rate the Supreme Court struck down in February 2026.
Passenger vehicles from Japan and patented pharmaceuticals from Japan sit under separate Section 232 actions with a 15% rate, and many Chapter 30 medicines are exempt from the Section 301 duty.
Generic pharmaceuticals are not subject to the Section 232 pharmaceutical tariff at this time, and some specialty therapies can qualify for a zero rate.
The $800 de minimis exemption remains suspended for all countries, so small packages from Japan need a formal or informal entry and pay applicable duties.
Always confirm the rate for your exact HTSUS number, country of origin and entry date with your customs broker before you price or ship.
US tariffs on Japan have changed three times since the 2025 US-Japan trade deal was announced, so a rate quoted last year may no longer be the rate CBP collects. As of October 2026, most products of Japan pay a Section 301 duty that brings the total of the normal duty plus the new duty to 12.5%. Passenger vehicles and patented pharmaceuticals follow separate Section 232 rules at 15%, and a long list of medicines and raw materials is exempt from the Section 301 duty altogether.
This guide explains how US Japan tariffs work today, what changed after the Supreme Court ruled on the earlier emergency tariffs, how pharmaceutical and medical device importers are affected, and how to check the rate for a specific product. Tariff rules move quickly. Treat every figure here as a snapshot checked against official sources in October 2026, and confirm it with your customs broker on the day you enter goods.
How the 2025 US-Japan trade deal became today's tariff framework
The US Japan trade deal was announced in July 2025. The White House fact sheet from July 23, 2025 described a baseline 15% tariff on imports from Japan, a $550 billion Japanese investment commitment and new market access for US rice, autos and other goods. The 15% rate was first applied under the International Emergency Economic Powers Act (IEEPA), using Chapter 99 headings such as 9903.02.72 and 9903.02.73 for goods entered from August 7, 2025.
That legal basis did not last. According to a CBP interim final rule published in the Federal Register on June 24, 2026, the Supreme Court decided Learning Resources, Inc. v. Trump on February 20, 2026 and held that IEEPA does not authorize the President to impose tariffs. Executive Order 14389 then ended the IEEPA tariff actions. The same day, Proclamation 11012 imposed a temporary 10% import surcharge under Section 122 of the Trade Act of 1974 for a period of 150 days.
The current framework for tariffs from Japan to US buyers took shape in July 2026. The Office of the US Trade Representative closed 60 Section 301 investigations into forced labor import prohibitions, including one on Japan, and imposed new duties effective July 24, 2026. In parallel, Section 232 national security tariffs on autos, metals, semiconductors and patented pharmaceuticals continue to run on their own tracks.
What are the US tariffs on Japan?
As of October 2026, most goods of Japan pay a Section 301 duty set so that the normal US duty plus the Section 301 duty equals 12.5%. If the normal rate is already 12.5% or higher, the Section 301 duty is zero. This comes from the USTR notice of action published in the Federal Register on July 28, 2026, which states that for a product of Japan with a most-favored-nation (MFN) rate under 12.5%, the sum of the MFN tariff and the Section 301 tariff shall be 12.5%. Japan shares this treatment with South Korea and Switzerland. The EU and Taiwan have a similar cap at 10%.
The Section 301 duty does not apply to everything. The notice exempts goods listed in its annexes, including many raw materials, certain chemicals for pharmaceutical use, a list of Chapter 30 medicines, donations such as medicine intended to relieve human suffering, informational materials, civil aircraft articles, and goods that already pay Section 232 duties. Those Section 232 goods include steel, aluminum and copper articles, passenger vehicles and light trucks and their parts, medium and heavy-duty vehicles, wood products, semiconductor articles and, from July 31, 2026, patented pharmaceutical articles.
The table below summarizes the main layers that make up US tariffs on Japan for healthcare and life science importers. It is a starting point for a conversation with your broker, not a rate ruling.
Product type from Japan | Main tariff layer as of October 2026 | HTSUS Chapter 99 reference | What to confirm |
|---|---|---|---|
Most goods, including many medical devices, lab instruments and consumables | Section 301 duty that tops the MFN rate up to a combined 12.5% | 9903.05.49 (MFN under 12.5%) or 9903.05.48 (MFN 12.5% or higher) | Whether your HTSUS line appears in an exemption annex |
Medicines listed in the Section 301 exemption annex, such as many products in headings 3002, 3003 and 3004 | No Section 301 duty, normal MFN rate applies | 9903.05.86 | Exact subheading and whether Section 232 applies |
Chemicals listed for pharmaceutical applications | No Section 301 duty when used in pharmaceutical applications | 9903.05.89 | End use documentation for the shipment |
Patented pharmaceuticals and associated ingredients | Section 232 rate of 15% for products of Japan, unless a lower rate applies | 9903.04.62 | Patent status, company agreements and zero-rate eligibility |
Passenger vehicles and light trucks | Section 232 combined rate of 15% | 9903.94.41 (MFN under 15%) | Vehicle classification and parts treatment |
Semiconductor articles | Section 232 duty | 9903.79.01 | Whether the article falls within the Section 232 scope note |
The practical takeaway is that the Japan tariffs US importers pay now depend more on the HTSUS line than on the country alone. Two shipments from the same Japanese supplier can carry different duties if one is a patented drug, one is a diagnostic analyzer and one is a reagent listed in an exemption annex.
A worked example for a medical device
Take a Japanese medical instrument classified in HTSUS 9018.19.95, which the Harmonized Tariff Schedule lists with a general rate of Free. If that line is not in an exemption annex, the Section 301 heading 9903.05.49 applies and the combined rate becomes 12.5% of the customs value. On a $40,000 entry, that is $5,000 in Section 301 duty, plus merchandise processing and harbor maintenance fees where they apply. The same arithmetic changes if the device is classified elsewhere, so the classification step matters more than ever. Our guide to finding the right HS code for international shipping walks through that method.
What tariffs does Japan have on the US?
Japan applies its own customs tariff to US goods, and there is no Japanese tariff that mirrors the US Section 301 or Section 232 duties. Japan Customs explains that the applied rate is generally the lower of the WTO rate and the general or temporary rate, with lower rates available under Japan's economic partnership agreements for goods that qualify. Japan also charges consumption tax on imports at 10% standard or 8% reduced, calculated on the customs value plus customs duty and any excise taxes.
For US exporters, the 2019 US-Japan Trade Agreement still matters. USTR describes that agreement as eliminating or reducing tariffs on certain agricultural and industrial products, with Japan's commitments set out in Annex 1. The 2025 deal added purchase and market access commitments, such as higher US rice imports and acceptance of US automotive standards, according to the White House fact sheet.
So when people ask what tariffs does Japan have on the US, the honest answer is that it depends on the product. For healthcare exporters, the picture is often simple. Japan's current tariff schedule lists medicaments in heading 30.04 as Free, so the main import cost for a US drug shipped to Japan is usually the consumption tax, regulatory approval and logistics rather than duty. Confirm the current rate for your line in the Japan Customs tariff schedule or with your importer of record in Japan.
How does the US-Japan trade deal affect pharmaceutical imports?
The US-Japan trade deal set the 15% ceiling that now applies to patented pharmaceuticals from Japan under Section 232, while generic medicines and many listed medicines avoid the new Section 301 duty. The April 2026 Section 232 proclamation on pharmaceuticals sets a 100% default rate on patented pharmaceuticals and associated ingredients listed in its Annex I, then lowers it to 15% for products of Japan, the European Union, South Korea, and Switzerland and Liechtenstein, unless a lower rate applies. The proclamation says it implements pharmaceutical commitments in existing trade deals with those partners.
Several details shape the real pharmaceutical imports from Japan tariff:
Generic pharmaceuticals and their associated ingredients are not subject to the Section 232 pharmaceutical tariffs at this time, according to the proclamation.
The duties took effect on July 31, 2026 for companies listed in Annex III of the proclamation and on September 29, 2026 for other companies.
A zero rate can apply to orphan drugs, nuclear medicines, plasma derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates and certain medical countermeasures, if the Commerce Secretary determines the product comes from a jurisdiction with a qualifying trade agreement or meets an urgent US health need.
Companies with approved onshoring plans that have also signed most-favored-nation pricing agreements with HHS can receive a zero rate until January 20, 2029.
The Section 301 forced labor duty does not stack on patented pharmaceutical articles already covered by Section 232 headings 9903.04.60 through 9903.04.66, under a change in the July 2026 USTR notice effective July 31, 2026.
For a life science company, this means the first question is no longer only "what is the HTSUS code" but also "is this product patented, which company made it, and does it qualify for a zero rate". Cell therapy shipments, biologics and clinical trial material each need that review before the first entry. Our overview of how US pharma tariffs affect costs, supply and trade covers the wider sector impact, and the broader guide to tariffs and duties for healthcare explains how duties, fees and valuation interact.
Temperature-sensitive products add a timing risk. A shipment of Japanese biologics held at the border because the importer cannot document patent status or zero-rate eligibility still needs its cold chain maintained. Planning the documentation and the specialty cold chain together reduces the chance that a paperwork question becomes a temperature excursion.
Do small packages from Japan pay US tariffs?
Yes. The $800 de minimis exemption is suspended for all countries, so small packages from Japan are generally subject to duties, taxes and fees and need an entry. The CBP rule published on June 24, 2026 explains that Executive Order 14388 of February 20, 2026 continued the suspension of duty-free de minimis treatment, including for shipments sent through the international postal network, even after the Supreme Court decision on IEEPA tariffs.
A common search is US import tariffs Japan products small packages, and the answer has three parts:
Courier and express shipments valued at $800 or less no longer enter duty free. CBP published a separate rule suspending de minimis for all modes other than the international postal network.
For mail, CBP's interim final rule suspending the exemption for postal shipments took effect on July 24, 2026, and it created a new postal informal entry process. The rule set a compliance date of October 22, 2026 for certain data requirements. Check with your carrier or broker whether that compliance date has since been changed.
Congress has repealed the statutory de minimis exemption effective July 1, 2027, under Public Law 119-21, so the suspension is not expected to reverse before that date.
For healthcare shippers, small packages often mean samples, spare parts, reagents or replacement components sent by express courier. Each now needs a correct HTSUS number, country of origin and value, and the Section 301 or Section 232 rate applies just as it would on a larger entry. Building that data into the commercial invoice before the package leaves Japan is the simplest way to avoid holds. If you move these shipments regularly, compare international parcel options that include customs entry preparation.
How do importers check the current tariff on a Japanese product?
Start with the exact HTSUS number and the entry date, then check every Chapter 99 heading that could apply. A reliable routine looks like this:
Confirm the 10-digit HTSUS classification for the product. Use binding rulings or a broker review for anything new or borderline.
Look up the general (MFN) rate in the current edition of the Harmonized Tariff Schedule at hts.usitc.gov.
Check whether the line falls under a Section 232 action, for example pharmaceuticals in headings 9903.04.60 through 9903.04.66, autos in the 9903.94 series, or semiconductors in 9903.79.01.
If no Section 232 action applies, check whether the line is listed in an exemption annex of the July 2026 Section 301 notice. If not, apply heading 9903.05.49 or 9903.05.48 for products of Japan.
Confirm the country of origin under CBP rules. Goods shipped from Japan but made elsewhere follow the origin country's rate.
Check for any later Federal Register notice or CBP Cargo Systems Messaging Service (CSMS) message that changes the rate, the effective date or the exemption list.
Your licensed customs broker is the right party to confirm the final entry lines, and CBP is the authority on scope questions. The Section 301 notice itself says questions about the scope of particular HTSUS provisions should be referred to CBP. A customs brokerage team can run this check before goods ship, and an active US customs bond is needed for formal entries.
What US Japan tariffs mean for healthcare supply chains
The move from a flat 15% emergency tariff to a 12.5% cap with wide exemptions lowers duty on some Japanese healthcare goods and leaves others unchanged. Medical devices with a Free MFN rate that are not on an exemption list now carry a 12.5% combined rate instead of 15%. Many medicines in Chapter 30 avoid the Section 301 duty, but patented drugs face the 15% Section 232 rate unless a zero rate applies.
Importers who paid IEEPA duties on Japanese goods should ask their broker whether those entries qualify for a refund under CBP's published IEEPA refund procedures. Refund eligibility depends on entry status and liquidation, so it needs an entry-by-entry review.
A few planning steps help regardless of how the rates move next:
Keep a product master file with HTSUS number, origin, patent status and the Chapter 99 heading used on the last entry.
Recheck the rate when a new Federal Register notice is published, not only at contract renewal.
Put duty assumptions in purchase orders and quotes with a date, so cost changes can be traced.
Coordinate the customs plan with the shipping plan for time-sensitive and temperature-controlled goods.
Two separate actions are still worth watching. USTR also opened Section 301 investigations into structural excess capacity in manufacturing that name several economies, and the Section 232 pharmaceutical proclamation allows rates to rise if partner commitments are not met. Either could change Japan tariffs US importers pay. Our article on how US-EU tariff changes affect your business shows how a similar capped structure applies to European goods.
Shipping healthcare goods from Japan with fewer surprises
Mercury handles customs brokerage, air freight and temperature-controlled shipping for life science and healthcare companies importing medical devices, biologics, reagents and clinical materials. If you are reviewing how US tariffs on Japan apply to your product list, our brokerage team can check classifications and Chapter 99 headings before your next shipment leaves Japan.



